Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C
Resources
Showing 201 to 210 of 249 resources
-
Evaluation of the pilot provision of single use plastic water ampoules to people who inject drugs in Glasgow
Greater Glasgow and Clyde (GG&C) has an estimated injecting population of 8862. There are 74 Injecting Equipment Provision (IEP) outlets across the area to meet the paraphernalia needs of this population. Since 2009 GG&C has provided a comprehensive package of paraphernalia, including needle choice, spoons, filters, citric acid and swabs. However, until the start of this pilot, water for injecting (WFI) was not available from any of the 62 pharmacy outlets. In fact prior to the pilot only 3 outlets provided WFI and this was in a glass ampoule form.Scotland Sep 2012 Case study, Reports & Research PDF -
Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965
Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United States. Many of the 2.7–3.9 million persons living with HCV infection are unaware they are infected and do not receive care (e.g., education, counseling, and medical monitoring) and treatment. CDC estimates that although persons born during 1945–1965 comprise an estimated 27% of the population, they account for approximately three fourths of all HCV infections in the United States, 73% of HCV-associatedRest of World 17 Aug 2012 Reports & Research PDF -
National survey of hepatitis C services in prisons in England, July 2012
This is the first dedicated survey of hepatitis C services in prisons in England. The survey aim was to collect basic information on what type of services are provided in prisons for the diagnosis, treatment and follow-up of prisoners infected by hepatitis C.England Jul 2012 Reports & Research PDF -
Hepatitis C in the UK - 2012 Report
The most recent national estimates in 2012 suggested that around 216,000 individuals were chronically infected with hepatitis C (HCV) in the UK. Both hospital admissions and deaths from HCV-related end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) are continuing to rise. In England, statistical modelling predicts that 15,840 individuals will be living with HCV-related cirrhosis or HCC in England in 2020 if left untreated.UK Jul 2012 Reports & Research PDF -
Hepatitis C Prevalence and Incidence among Scottish Prisoners and Staff Views of its Management: Final Report
This report aims to generate reliable data on prevalence and incidence of hepatitis C to inform the Scottish Prison Service and the NHS to develop effective needs-led interventions for hepatitis C (HCV) infected prisoners, and to enable an informed assessment of the effectiveness of measures to prevent the spread of blood borne viruses, especially hepatitis C, within the prison setting, as outlined in the Hepatitis C (Phase (II)) Action Plan for Scotland (2008).England, Scotland May 2012 Reports & Research PDF -
Deaths from liver disease: Implications for end of life care in England - March 2012
This report presents key facts about deaths from liver disease in England. It highlights differences in place and cause of death by age, sex and deprivation. It is aimed at commissioners and providers of end of life care, clinicians caring for patients with liver disease, and others concerned with providing quality end of life care for this patient group, including patients themselves and their carers. The report gives the first summary of high level statistics on deaths from liver disease on which future discussions can be built.England Mar 2012 Reports & Research PDF -
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
This paper reports on the results of a 2011 EASL meeting and subsequent dialogue with patient groups and relevant experts in Europe. It summarises the current knowledge of HCV infection and the brain; prevalence, course, and neurobiology of IFN-a associated psychiatric side effects; possible risk factors for IFN-a associated depression and suicide attempts; psychiatric management of HCV infected patients before and during antiviral treatment; prevention of IFN- a associated psychiatric side effects; and psychiatric aspects of the new antivirals.UK, Rest of World 2012 Reports & Research PDF -
The Silent Pandemic: Tackling Hepatitis C with Policy Innovation
Hepatitis C may be the serious disease that most combines widespread prevalence with widespread ignorance. According to the World Health Organisation (WHO), this urgent public health problem kills 350,000 people per year, and 150 million have the chronic form of the hepatitis C virus (HCV). The incidence of new infections is simply not known at the global level. Yet, HCV is entirely preventable and largely curable.UK, Rest of World 2012 Reports & Research PDF -
Improving outcomes and supporting transparency. Part 1: A public health outcomes framework for England, 2013-2016
The responsibility to improve and protect our health lies with us all – government, local communities and with ourselves as individuals.England Jan 2012 Reports & Research, Strategy & Planning PDF -
Yorkshire and the Humber Quality Standards Framework for Hepatitis B and C: 2012
In order to address the prevention and burden of hepatitis C (and B) effectively it is important that the four key elements of the pathway are in place as defined by the Department of Health. Whilst there have been many developments since 2004, this Quality Standards Framework still focuses on the four key elements of the hepatitis B and C pathway but provides more detail on how, in Yorkshire and the Humber, stakeholders can work effectively to deliver a quality pathway to patients regarding hepatitis B and C.Yorkshire and the Humber 2012 Other, Reports & Research PDF